The study showed that these combination therapies prevent the emergence of what is known as drug resistance.
All virus treatments based on monoclonal antibodies work by interfering with the interaction between the protein and cells.
Antibodies can be described as warriors in immune systemWhen the Corona virus infects the body, the antibodies stick to the spiny protrusions on the surface of the virus and prevent it from entering cells.
Last May, the US Food and Drug Administration granted emergency use authorization for an anti-Covid-19 drug produced by GlaxoSmithKline, in cooperation with the Vir Biotechnology Company.
The administration said in a statement that “sotrovimab”, an experimental monoclonal antibody treatment, has been authorized to treat COVID-19 in mild to moderate cases, in adults and children 12 years of age and older, as well as at risk of developing an infection. severe.
The two companies said in a separate statement that the treatment would be available to appropriate patients in the United States “in the coming weeks”, and added that they planned to apply for full approval for the treatment “during the second half of 2021.”
GlaxoSmithKline and Fair indicated that the drug has been shown to reduce the risk of hospitalization or death in adults at high risk, by 85 percent, after a trial of 868 patients.
Monoclonal antibodies are proteins made in a laboratory that mimic the immune system’s ability to fight viruses.
The former US president praised Donald Trumpwith a research monoclonal antibody made by the pharmaceutical company Regeneron, which he was treated with when he was infected. with covid-19 Late last year, the US Food and Drug Administration authorized the treatment in late November.
And the American authority has also previously approved another antibody treatment, produced by Eli Lilly.